NUCALA (mepolizumab) is a monoclonal antibody developed by GlaxoSmithKline that is designed to reduce inflammation driven by eosinophils, a type of white blood cell involved in multiple inflammatory diseases. By binding to interleukin-5 (IL-5), NUCALA prevents IL-5 from attaching to its receptor on eosinophils, thereby lowering eosinophil levels in the blood and tissues.

It is approved for use as an add-on maintenance treatment for:

• Severe eosinophilic asthma in patients aged 6 years and older whose asthma remains uncontrolled despite high-dose inhaled corticosteroids and other standard therapies.

• Eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune condition causing blood vessel inflammation.

• Hypereosinophilic syndrome (HES) in patients aged 12 years and older.

• Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose symptoms are not controlled with standard therapies.

NUCALA is given as a subcutaneous injection (under the skin) once every 4 weeks. Clinical trials have shown that it helps reduce asthma exacerbations, improve quality of life, and lower the need for oral corticosteroids in eligible patients.